KEY FINDINGS: New Method to Detect the Type of Antibodies Linked to Inhibitors Development Among People with Hemophilia A and B
In an article release by the CDC (Center for Disease Control and Prevention), research reports key findings related to the formation of inhibitors (antibodies) in patients who have hemophilia. The study shows that hemophilia A and hemophilia B patients who develop inhibitors are likely to have a specific type of antibody called immunoglobulin G subclass 4, or IgG4. In the event that traditional inhibitor tests do not provide clear results, testing for these antibodies instead may help clarify whether an inhibitor is present.
Inhibitors are antibodies (protein) that prevents or stops infused factor from working. For those with bleeding disorders like hemophilia A and hemophilia B, inhibitors often develop because the body’s immune system identifies the clotting factor as foreign. A blood test called Nijmegen-Bethesda Assay (NBA) is used to diagnose inhibitors.
For some cases, NBA can produce an unclear result as to whether a patient has an inhibitor or not. The CDC researchers have addressed this problem by developing a complementary test. A new method called fluorescence immunoassay (FLI). Blood samples from patients with hemophilia A were use to detect antibodies for factor VIII. As well as blood samples from patient with hemophilia B to detect antibodies for factor IX.
For the complete article: CLICK HERE